Compare BWMN & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWMN | CAPR |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.6M | 584.9M |
| IPO Year | 2021 | 2011 |
| Metric | BWMN | CAPR |
|---|---|---|
| Price | $42.91 | $7.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $43.00 | $27.00 |
| AVG Volume (30 Days) | 336.3K | ★ 2.6M |
| Earning Date | 11-17-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 329.41 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $490,017,000.00 | N/A |
| Revenue This Year | $21.26 | N/A |
| Revenue Next Year | $18.02 | $1.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.88 | N/A |
| 52 Week Low | $25.07 | $2.96 |
| 52 Week High | $45.00 | $40.37 |
| Indicator | BWMN | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 77.93 | 51.07 |
| Support Level | $42.39 | $6.01 |
| Resistance Level | $43.14 | $10.73 |
| Average True Range (ATR) | 0.06 | 0.54 |
| MACD | -0.07 | 0.11 |
| Stochastic Oscillator | 84.09 | 90.20 |
Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.